Van Khanh Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Van Khanh Nguyen has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Gozo Kiguchi
Department of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan
1 shared publication - Hidekazu Yamamoto
Department of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan
1 shared publication - Hideyuki Matsushima
Department of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan
1 shared publication - Hiroki Kato
Department of Mathematics and Statistics in Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto City 602-8566, Kyoto, Japan
1 shared publication - Hisashi Kosaka
Department of Hepatobiliary Surgery, Kansai Medical University, Hirakata, Japan
1 shared publication - Hoang Hai Duong
Department of Hepatobiliary Surgery, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata 573-1010, Osaka, Japan
1 shared publication
Latest Publications
- Open Access
Association Between Cumulative Chemotherapy Exposure and Survival Outcomes in Advanced Biliary Tract Cancer
Background: This study evaluated the association between cumulative chemotherapy exposure and overall survival (OS) in patients with advanced biliary tract cancer (BTC) and explored baseline factors associated with prolonged treatment continuation. Methods: Patients with advanced BTC receiving systemic chemotherapy were stratified by cumulative chemotherapy exposure (p < 0.001). Multivariable logistic regression identified metastatic disease as an independent factor associated with a lower likelihood of receiving ≥8 cycles (OR 0.34, 95% CI 0.12–0.97, p = 0.044). In landmark-adjusted multivariable analysis (n = 66), receiving ≥8 chemotherapy cycles remained independently associated with longer OS (HR 0.46, 95% CI 0.22–0.96, p = 0.039). Restricted cubic spline analysis demonstrated progressive hazard reduction with increasing chemotherapy exposure, although the magnitude of reduction attenuated beyond approximately 8 cycles. Conclusion: Greater cumulative chemotherapy exposure was associated with prolonged OS in advanced BTC, with attenuation of the survival benefit beyond approximately 8 cycles. Sustained treatment exposure may partly reflect preserved physiological reserve and ability to maintain systemic therapy in real-world clinical practice.
Open AccessAssociation Between Cumulative Chemotherapy Exposure and Survival Outcomes in Advanced Biliary Tract Cancer
Background: This study evaluated the association between cumulative chemotherapy exposure and overall survival (OS) in patients with advanced biliary tract cancer (BTC) and explored baseline factors associated with prolonged treatment continuation. Methods: Patients with advanced BTC receiving systemic chemotherapy were stratified by cumulative chemotherapy exposure (p < 0.001). Multivariable logistic regression identified metastatic disease as an independent factor associated with a lower likelihood of receiving ≥8 cycles (OR 0.34, 95% CI 0.12–0.97, p = 0.044). In landmark-adjusted multivariable analysis (n = 66), receiving ≥8 chemotherapy cycles remained independently associated with longer OS (HR 0.46, 95% CI 0.22–0.96, p = 0.039). Restricted cubic spline analysis demonstrated progressive hazard reduction with increasing chemotherapy exposure, although the magnitude of reduction attenuated beyond approximately 8 cycles. Conclusion: Greater cumulative chemotherapy exposure was associated with prolonged OS in advanced BTC, with attenuation of the survival benefit beyond approximately 8 cycles. Sustained treatment exposure may partly reflect preserved physiological reserve and ability to maintain systemic therapy in real-world clinical practice.